Loading
A phase 1/2 trial of Tafasitamab, Lenalidomide in diffuse large b-cell lymphoma, run by Incyte Biosciences Japan GK, active and no longer recruiting.
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) is a phase 1/2 interventional study registered as NCT04661007 by Incyte Biosciences Japan GK, with 72 participants enrolled, started 2020-12-15 and due to reach its primary completion in 2025-07-01. Interventions recorded: tafasitamab, lenalidomide, parsaclisib, R-CHOP. Conditions listed: Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma. No results are recorded here; the registry entry is the source.
Shares Tafasitamab, Incyte, Lenalidomide, PROTACs & molecular glues (targeted protein degradation).
Shares Tafasitamab, Incyte, Lenalidomide, PROTACs & molecular glues (targeted protein degradation).
Shares Tafasitamab, Incyte, Lenalidomide, Monoclonal antibodies.
Shares Tafasitamab, Incyte, Monoclonal antibodies.
Shares Parsaclisib, Incyte.
Shares Tafasitamab, Incyte, Lenalidomide, PROTACs & molecular glues (targeted protein degradation).
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Monoclonal antibodies.
Shares Tafasitamab, Lenalidomide, Monoclonal antibodies, Diffuse large B-cell lymphoma.